Menopause & Andropause — micro-course
A free, postgraduate-level taster of the Menopause & Andropause CAS. Work the micro-course, then complete the synoptic to earn a downloadable, personalised CPD certificate.
Reviewed and kept current
Last editorial review: 6 June 2026 · Next scheduled refresh: 1 September 2026.
Half the population, two decades of life, one of the largest under-served care domains in the NHS
Menopause occurs in essentially all women who reach midlife; testosterone deficiency syndrome (TDS, or symptomatic male hypogonadism) is detectable in approximately a third of UK men over 60. The clinical, cardiometabolic and psychosocial consequences of mismanaged or unmanaged hormonal transitions are amongst the largest preventable disease burdens in the NHS. The 2022 UK Women’s Health Strategy, the 2023 ESC women’s cardiovascular disease guideline, the IMS 2025 midlife health recommendations, and the ESE 2025 Clinical Practice Guideline have collectively reframed the discipline as a multisystem clinical specialty rather than a symptom-management afterthought.
What changed. Three convergent pieces of guidance have re-defined contemporary primary-care practice in this field: the NICE NG23 2024 update (clinical diagnosis ≥ 45 years without FSH testing); the joint BMS-BSGE-BGCS-FSRH-GIRFT-RCOG-RCGP guideline on unscheduled bleeding on HRT (Manley et al, 2024); and NICE TA1143 recommending fezolinetant for vasomotor symptoms in women for whom hormone therapy is contraindicated or unsuitable. Add to that the BSSM 2022 testosterone deficiency guideline and the landmark TRAVERSE cardiovascular safety trial (Lincoff, NEJM 2023) and the discipline now has the evidence base that its practitioners deserve.
Learning objectives — by the end of this micro-course you will be able to
How this maps to the CAS
This taster previews the clinical strands of the Menopause & Andropause Certificate of Advanced Studies (CAS) — a standalone FHEQ Level 7 award of 20 UK credits / 10 ECTS (200 notional hours), delivered as a 10-week online cohort and awarded by New Vision University (Tbilisi, Georgia). The strands below are taught as one connected programme within the single CAS, not as separate qualifications.
Menopause Foundations & HRT
STRAW+10 staging; clinical diagnosis ≥ 45 without FSH; HRT regimens — transdermal versus oral, sequential versus continuous, micronised progesterone, LNG-IUS, tibolone; the timing hypothesis; absolute risk communication using the NICE discussion aid; annual review and de-prescribing decisions.
Bleeding, Endometrial Safety & Non-Hormonal Pathways
The joint BMS-RCOG 2024 unscheduled bleeding flowchart; major and minor endometrial cancer risk factors; transvaginal ultrasound thresholds; fezolinetant under NICE TA1143; SSRIs / SNRIs (with the paroxetine-tamoxifen interaction); CBT for menopause; complementary therapies; emerging NK3 dual antagonists.
Special Populations & Long-Term Consequences
POI (Davis Lancet 2024 Commission); ER-positive breast cancer survivors (NG215); migraine with aura; ADHD + perimenopause; perimenopausal contraception (FSRH UKMEC); cardiometabolic shift (Ravindran-Varma 2026); bone health; brain and cognition; genitourinary syndrome of menopause; transgender care.
Andropause & Male Longevity
BSSM 2022 testosterone deficiency framework; symptom + biochemistry confirmation; the 7-am rule; SHBG and free testosterone calculation; TRT options — gels, intramuscular enanthate, undecanoate; TRAVERSE 2023 cardiovascular safety with the AF / AKI nuance; monitoring; fertility-preserving clomiphene; testosterone in women for HSDD (BMS 2022 off-label).
HPO-axis decline, KNDy neurons, and the cardiometabolic shift
The reason menopause and andropause sit on the same CAS curriculum is that both are hormonal transitions producing predictable multisystem consequences. The therapeutic implication is symmetrical: replace what has been lost, where doing so is safe, accessible, and aligned with the patient’s priorities.
The female transition — STRAW+10 staging
The Stages of Reproductive Aging Workshop +10 (STRAW+10) is the international consensus framework for staging reproductive ageing. It defines reproductive, menopause-transition (early and late), and postmenopause stages by menstrual cycle changes, FSH and AMH biomarkers, and antral follicle count. In UK primary-care practice, STRAW+10 informs counselling but does not replace the NICE NG23 ≥ 45-year clinical diagnosis without FSH testing.
| STRAW+10 stage | Menstrual feature | Endocrine / clinical signal |
|---|---|---|
| Reproductive (-5 to -3) | Regular cycles | Normal FSH; AMH falling from age ~35. |
| Late reproductive (-3a, -3b) | Subtle changes in flow / length | FSH variable; AMH low; antral follicle count declining. |
| Early menopause transition (-2) | Persistent ≥ 7-day cycle-length variation | FSH variable, often elevated in early follicular phase. |
| Late menopause transition (-1) | Interval of amenorrhoea ≥ 60 days | FSH ≥ 25 IU/L; vasomotor symptoms frequent. |
| Early postmenopause (+1a, +1b, +1c) | ≥ 12 months amenorrhoea | Stabilised high FSH, low oestradiol; VMS peak; bone-loss acceleration. |
| Late postmenopause (+2) | Continued amenorrhoea | Genitourinary syndrome of menopause becomes dominant; cardiometabolic risk profile shifts. |
The KNDy neuron — why fezolinetant works
Vasomotor symptoms originate in the hypothalamus, specifically in the kisspeptin / neurokinin B / dynorphin (KNDy) neurons of the infundibular nucleus. In the reproductive years, oestradiol exerts negative feedback on KNDy neurons, suppressing neurokinin B (NKB) tone. As oestradiol falls during menopause, NKB tone rises and KNDy neurons hypertrophy, becoming hyperactive at the median preoptic nucleus thermoregulatory site — the proximate trigger for the hot flash. Fezolinetant is a selective NK3 receptor antagonist that blocks NKB at the KNDy neuron, restoring thermoregulatory tone without an oestrogen effect anywhere else in the body. This mechanism is why fezolinetant works without uterine, breast or thrombotic effects — and why it represents the first genuinely targeted non-hormonal vasomotor therapy.
Translational pearl. The KNDy mechanism explains both the speed of fezolinetant’s effect (clinically meaningful within one week, plateauing at four weeks) and its secondary insomnia benefit — restoring thermoregulatory tone reduces nocturnal vasomotor episodes and improves sleep architecture without the GABAergic side-effect profile of benzodiazepines or the next-day sedation of antihistamines.
Mind map — the cardiometabolic shift at menopause
Menopause is not purely a vasomotor or genitourinary phenomenon. It is a cardiometabolic phase change. The figure below — drawn from the Ravindran-Varma 2026 InnovAiT update on precision menopause treatment — shows the eight-way radial of menopausal cardiometabolic biology with explicit therapeutic levers per spoke.
Eight-way radial of the menopausal transition. Adapted from Ravindran N, Varma R. Cardiometabolic changes at menopause — time for precision menopause treatment. InnovAiT 2026.
The male transition — andropause / TDS
Testosterone deficiency syndrome (TDS, also called late-onset hypogonadism, andropause, partial androgen deficiency of the ageing male) is biologically distinct from female menopause. It is a slow, partial, often heterogeneous decline rather than an abrupt cessation. Total testosterone falls by approximately 1–2% per year from age 40, with sex-hormone-binding globulin (SHBG) rising in parallel and reducing free (bioavailable) testosterone proportionately more. Symptomatic confirmation requires both clinical features and biochemistry on two morning samples, per BSSM 2022.
| Threshold | BSSM 2022 interpretation | Action |
|---|---|---|
| Total T < 8 nmol/L | Confirmed testosterone deficiency | If symptomatic, offer TRT after counselling and excluding contraindications. |
| Total T 8–12 nmol/L | Grey zone | Calculate free testosterone (use the Vermeulen calculator); check LH, FSH; consider trial of TRT in symptomatic men with low FT or low normal LH (suggesting central origin). |
| Total T > 12 nmol/L | Generally normal | If symptoms persist, exclude alternative causes (depression, OSA, alcohol, anaemia, thyroid, medications, primary sexual dysfunction). |
The 7-am rule. Testosterone follows a circadian rhythm with a peak in the early morning. Both samples for diagnosis should be taken between 07:00 and 11:00, ideally on different mornings (BSSM 2022). Reference ranges quoted by laboratories represent population distributions; the BSSM “action levels” refer specifically to symptomatic men. A laboratory “normal” testosterone of 8.4 nmol/L in a man with reproducible symptoms still triggers the diagnostic pathway.
Clinical diagnosis above 45 in women; symptom-plus-biochemistry confirmation in men
The most consequential single message of NICE NG23 is that menopause in women aged 45 or older is a clinical diagnosis. Routine FSH and oestradiol testing in this age group is a positive harm — it adds cost, delays treatment, and frequently produces normal results that mislead clinicians into withholding effective therapy. Below 45, biochemistry remains relevant; below 40, the threshold for premature ovarian insufficiency, the diagnosis is biochemical with strict criteria.
Menopause diagnostic algorithm — adapted from NICE NG23 (2024 update)
Age ≥ 45 years with vasomotor or other typical symptoms
Diagnose perimenopause / menopause clinically. Do not test FSH unless there is diagnostic uncertainty (e.g. on contraception that suppresses cycles). Counsel on therapeutic options. Document in the record.
Age 40–44 years with menopausal-pattern symptoms
Test FSH on two occasions 4–6 weeks apart; both above 30 IU/L (with low oestradiol) supports a diagnosis of early menopause. NICE NG23 lowers the testing threshold here because spontaneous fertility is still relevant.
Age < 40 years with oligo / amenorrhoea ≥ 4 months
Diagnose premature ovarian insufficiency (POI) per ESHRE 2024 / Davis Lancet 2024 Commission criteria: FSH > 25 IU/L on two occasions ≥ 4 weeks apart. Refer to gynaecology / fertility specialist. Initiate HRT (or COC) for cardiovascular and bone protection at least until average age of natural menopause (~ 51 years).
Surgical or iatrogenic menopause at any age
Bilateral oophorectomy, chemotherapy- or radiotherapy-induced ovarian failure, GnRH-analogue therapy. Sudden, severe symptoms; high rate of long-term consequences. HRT initiation pre- or peri-operatively wherever possible (ESE 2025 strong recommendation).
Practical NG23 pearl. Three NHS rejections to remove from your practice: (a) “your FSH is not menopausal” in a 50-year-old with classic symptoms — wrong, FSH not indicated; (b) “you’re too young for menopause” in a 41-year-old with reproducible night sweats — wrong, this is an indication to test; (c) “your symptoms must mean depression” in a 47-year-old without antecedent depression — wrong, vasomotor and mood symptoms cluster in the perimenopause and respond to HRT before they respond to SSRIs.
Andropause / TDS diagnostic algorithm — BSSM 2022
Identify clinical features
Sexual: low libido, erectile dysfunction, reduced morning erections, infertility. Physical: fatigue, reduced energy, sarcopenia, central adiposity, hot flushes (rare but described). Psychological: low mood, irritability, reduced concentration, “loss of mojo”. Use the Ageing Males’ Symptoms (AMS) scale or equivalent for structured assessment.
Two morning samples · 07:00–11:00 · ≥ 1 week apart
Total testosterone, SHBG, LH, FSH. Ideally fasting. Avoid acute illness. Check prolactin if LH suppressed and TT low (consider pituitary cause). Calculate free testosterone using SHBG and albumin (Vermeulen formula).
Interpret against BSSM 2022 thresholds
TT < 8 nmol/L confirmed deficiency; 8–12 grey zone with calculation of free T; > 12 generally normal. Exclude reversible causes — alcohol, opioids, ketoconazole, glucocorticoids, severe obesity, untreated OSA, depression.
Counsel and offer trial of treatment if appropriate
Counsel on benefits (energy, libido, mood, body composition, bone density), risks (erythrocytosis, fertility suppression, AF / AKI signal from TRAVERSE), and contraindications (untreated prostate cancer, breast cancer, Hb > 175 g/L, severe untreated OSA). 6-month trial; reassess symptoms and biochemistry.
The presentations that demand immediate triage and the prescribing safety pearls every practitioner must hold
Most menopause and andropause presentations are not red flags. The few that are matter disproportionately. Six high-yield red-flag clusters dominate primary-care safety conversations in this domain.
Postmenopausal bleeding
Any bleeding after 12 months of amenorrhoea, regardless of HRT status, is a 2-week-wait suspected cancer referral until proven otherwise (NICE NG12). The endometrial cancer prevalence in this group is 5–10%. Transvaginal ultrasound with endometrial thickness threshold 4 mm is the screening test; thicker requires hysteroscopy and endometrial sampling.
Unscheduled bleeding on HRT
The full pathway is in Section 05. Headlines: major risk factor (BMI ≥ 40, Lynch / Cowden, prolonged unopposed oestrogen) or three minor risk factors triggers the urgent-suspicion-of-cancer pathway. Heavy or persistent bleeding, two minor risk factors, bleeding more than six months from initiation, or bleeding more than three months after a dose change triggers urgent transvaginal ultrasound within six weeks.
New-onset breast change
New lump, skin change, nipple discharge, axillary lymphadenopathy. 2-week-wait suspected cancer referral (NICE NG12). HRT does not delay or obscure the workup. Family history at any age of first-degree relative breast cancer < 40 is a consideration for genetic referral and a tightening of the HRT discussion (BMS 2024).
VTE risk on oral oestrogen
Oral oestrogens carry a 2–4× VTE risk above background; transdermal oestrogen does not. Switch to transdermal in any patient with personal or strong family history of VTE, BMI ≥ 30, lupus anticoagulant, or peri-operative VTE risk. Stop HRT at least four weeks before major surgery if oral; transdermal can usually continue (BMS 2022).
New-onset migraine with aura on COC / oral HRT
New aura on combined hormonal contraception is an FSRH UKMEC 4 — stop the COC immediately. New aura on oral oestrogen-containing HRT requires switch to transdermal (BMS 2022 — aura is no longer a contraindication to transdermal HRT). Investigate first migraine with aura aged > 50 years for vascular causes per NICE NG150.
Andropause red flags
New-onset erectile dysfunction with cardiovascular risk factors — perform structured CV risk assessment and consider exercise stress test (ESC 2023). Sudden testicular asymmetry — ultrasound to exclude testicular tumour. Unexplained anaemia in a young hypogonadal man — investigate for haematological cause first, then confirm hypogonadism. Galactorrhoea or visual field defect — pituitary imaging.
Six high-impact prescribing safety pearls.
The single most consequential 2024 guideline for primary-care HRT prescribers
Unscheduled bleeding on HRT is one of the most common reasons for cessation of HRT and one of the most common reasons for gynaecology referral. The 2024 joint guideline — authored by the British Menopause Society in partnership with the British Society of Gynaecological Endoscopy, the British Gynaecological Cancer Society, the Faculty of Sexual & Reproductive Healthcare, Getting It Right First Time (GIRFT), the Royal College of General Practitioners and the Royal College of Obstetricians & Gynaecologists (Manley K, Hillard T et al, Post Reproductive Health 2024) — provides the first unified primary-care decision logic for these presentations. This section reproduces the pathway as an interactive flow diagram and provides the underlying risk-factor and ultrasound-threshold tables.
The bleeding-on-HRT decision flowchart
Adapted from the GIRFT-BMS Summary Guide (June 2024) and the BMS guideline (November 2024 update). The pathway above is for primary-care use; locally agreed direct-access ultrasound vs urgent-bleeding-clinic models will vary.
Major and minor endometrial-cancer risk factors — table
The 2024 guideline operationalises risk stratification as a count of major and minor factors. Any one major factor — or any three minor factors — moves the patient to the urgent-suspicion-of-cancer pathway irrespective of bleeding pattern.
| Category | Major risk factors (any one triggers USCP) | Minor risk factors (any three trigger USCP) |
|---|---|---|
| Anthropometric | BMI ≥ 40 kg/m² | BMI 30–39 kg/m² |
| Inherited cancer | Lynch syndrome · Cowden syndrome | — |
| Exposure to oestrogen without adequate progestogen | Oestrogen-only HRT > 6 months in a woman with a uterus · Tricycling HRT (quarterly progestogen) for > 12 months · Prolonged sequential HRT > 5 years started at age ≥ 50 · ≥ 12 months of norethisterone or medroxyprogesterone for < 10 days/month or micronised progesterone for < 12 days/month sequential | Unopposed oestrogen 3–6 months · Tricycling HRT 6–12 months · 6–12 months of norethisterone / MPA < 10 days/month or micronised progesterone < 12 days/month sequential · Disproportionate progestogen-to-oestrogen dose > 12 months (including expired 52 mg LNG-IUS) |
| Endometrial physiology | — | Anovulatory cycles (e.g. PCOS) · Diabetes mellitus |
TVS thresholds — by HRT regimen
| HRT regimen | Endometrial thickness threshold | Action above threshold |
|---|---|---|
| Sequential HRT (sHRT) | ≤ 7 mm reassuring | > 7 mm → USCP and endometrial assessment (outpatient hysteroscopy ± biopsy) |
| Continuous combined HRT (ccHRT) | ≤ 4 mm reassuring | > 4 mm → USCP and endometrial assessment |
| Tibolone | ≤ 4 mm reassuring (apply ccHRT-equivalent threshold) | > 4 mm → USCP and endometrial assessment |
| Oestrogen-only (post-hysterectomy) | Endometrial assessment not applicable; consider TVS for other pelvic pathology | Vaginal cuff / vault evaluation if symptomatic |
| Any regimen with incomplete visualisation | Treat as cannot-exclude | → USCP and endometrial assessment |
The GIRFT pearl. A primary-care optimisation of HRT — most often increasing the progestogen-to-oestrogen ratio, switching from oral to transdermal oestrogen, switching from norethisterone to micronised progesterone, or fitting a 52 mg LNG-IUS — resolves unscheduled bleeding in the majority of low-risk women within six months. The new pathway is therefore designed to keep low-risk women in primary care and accelerate the high-risk women through to two-week-wait gynaecology — both safer and more cost-effective.
Embedded knowledge check — bleeding pathway
Mini-SBA · 56-year-old woman with bleeding 5 months after starting ccHRT
A 56-year-old woman attends with three weeks of light vaginal spotting. She started continuous combined HRT (transdermal oestradiol 50 microgram patch + micronised progesterone 100 mg daily) five months ago for severe vasomotor symptoms. BMI 28 kg/m². No personal or family history of endometrial, ovarian, or colorectal cancer. Cervical screening up to date. No diabetes, no PCOS history. Examination unremarkable; speculum normal; bimanual normal. Per the BMS-RCOG 2024 pathway, what is the most appropriate next step?
Correct answer: B. She has unscheduled bleeding within 6 months of starting HRT, no major risk factors (BMI < 40, no Lynch / Cowden, no prolonged unopposed oestrogen) and no minor risk factors meeting the “3 of” threshold. Per the BMS-RCOG 2024 pathway, this is conservative-management territory: optimise the HRT (in this case, increasing progestogen given that 100 mg is the lower of the licensed continuous-combined doses) and reassess at six months. If bleeding persists at six months despite optimisation, an urgent transvaginal ultrasound (option C) becomes appropriate. USCP referral (A) requires either a major risk factor, three minor risk factors, or bleeding that is heavy, persistent, presenting more than 6 months after initiation, or more than 3 months after a dose change. Stopping HRT entirely (D) is not necessary and may not be acceptable given severe VMS. Primary-care endometrial biopsy (E) is not part of the 2024 pathway.
Transdermal-first thinking, micronised progesterone, and the LNG-IUS pathway
NICE NG23 (2024 update) and BMS 2024 endorse transdermal oestradiol with micronised progesterone or a 52 mg LNG-IUS as the contemporary first-line UK regimen for the majority of women requiring HRT. The clinical rationale is the favourable VTE, breast-cancer and gallstone safety profile of transdermal oestrogen combined with the body-identical, low-androgenic and low-VTE profile of micronised progesterone. Oral oestrogen retains a role, but the threshold for transdermal-first prescribing has moved decisively toward transdermal as the default.
HRT regimen decision logic — sequential versus continuous
Perimenopausal (still cycling, irregular cycles, age < 54 generally)
Use a sequential regimen — daily oestrogen plus progestogen for 10–14 days per cycle. The sequential regimen reproduces a regular withdrawal bleed, which is acceptable and predictable in this group. NICE NG23 / BMS 2024.
Postmenopausal (12 months amenorrhoea, or age ≥ 54)
Use a continuous combined regimen — daily oestrogen plus daily progestogen, no withdrawal bleed expected. Most women want to be bleed-free. Switch from sequential to continuous combined typically at 12 months of amenorrhoea or routinely after age 54.
Post-hysterectomy
Use oestrogen only — no endometrial protection required. Exception: women with prior endometriosis whose extra-uterine endometrial deposits may persist; consider a low-dose progestogen for 1–3 years post-hysterectomy in this group (BMS 2022).
Mirena (52 mg LNG-IUS) in situ
The LNG-IUS provides endometrial protection equivalent to a continuous progestogen for HRT purposes — this is off-licence but BMS-endorsed and is the preferred option for women already using the IUS for contraception or heavy menstrual bleeding. Replace at 5 years for HRT indication. Add transdermal or oral oestradiol; no additional progestogen needed.
Even-handed UK-licensed HRT pharmacology
| Component / agent | Routes & UK preparations | UK position / pearl |
|---|---|---|
| Oestradiol — transdermal | Patches: Estradot, Evorel, Estraderm MX, Femseven · Gels: Oestrogel, Sandrena · Sprays: Lenzetto · Microdose: Bedol | NICE NG23 first-line. Avoids first-pass hepatic effect; lower VTE risk; preferred in BMI ≥ 30, migraine with aura, gallbladder disease, hypertriglyceridaemia. |
| Oestradiol — oral | Elleste Solo, Premarin (CEE), Zumenon, Progynova | Greater convenience for some patients; carries 2–4× background VTE risk; modest hepatic-protein effects; appropriate where transdermal is impractical. |
| Micronised progesterone (Utrogestan) | Oral 100 mg or 200 mg capsule, also licensed vaginally; sequential = 200 mg nights 1–12 of cycle; continuous = 100 mg daily | Body-identical; non-androgenic; lowest breast-cancer signal among progestogens (E3N cohort, French collaborative). First-line per NICE NG23 / BMS 2024. |
| 52 mg LNG-IUS (Mirena) | Intrauterine; 5 years for HRT indication | Off-licence for HRT but BMS / NICE NG23 endorse. First-line where contraception or HMB co-indication. Replace at 5 years. |
| Norethisterone | Oral 1 mg or 5 mg sequential; combined patches Evorel Sequi, Evorel Conti, Femseven Conti | Synthetic 19-nor progestogen; androgenic; less favourable breast-cancer and lipid profile than micronised progesterone; useful in HMB context. |
| Medroxyprogesterone acetate (MPA) | Oral 2.5–10 mg; combined Indivina, Premique | Synthetic 21-carbon progestogen; in WHI was associated with the breast-cancer signal in combined HRT arm; less preferred where alternatives exist. |
| Dydrogesterone | Oral 5–10 mg sequential or 5 mg continuous; combined Femoston | Retro-progesterone; favourable breast-cancer signal in E3N; useful alternative for women who cannot tolerate micronised progesterone. |
| Tibolone (Livial) | Oral 2.5 mg daily; postmenopausal only (12 months amenorrhoea required) | Synthetic steroid with weak oestrogenic, progestogenic and androgenic activity; reduces VMS and improves bone density; small mood / libido benefit; LIBERATE study advised against use in breast-cancer survivors. |
| Conjugated equine oestrogen + bazedoxifene (Duavive) | Oral CEE 0.45 mg + bazedoxifene 20 mg | Tissue-selective oestrogen complex (TSEC); endometrial protection without progestogen; modest reduction in breast tissue density signal; option in women with progestogen intolerance. |
| Topical / vaginal oestrogen | Estriol cream (Ovestin), oestradiol vaginal tablets (Vagifem, Vagirux), oestradiol-releasing ring | Local-only effect for genitourinary syndrome of menopause; endometrial proliferation negligible at standard doses; safe in most breast-cancer survivors after MDT discussion (BMS / RCOG / NICE NG215). |
| Testosterone (women, off-licence) | AndroFeme 1% cream (off-licence import); Testogel sachets (off-licence) at 1/10th male dose | BMS 2022 supports for HSDD in postmenopausal women on adequate oestrogen replacement, after exclusion of relationship / mood / drug causes. Aim total T mid-female range; check at 3 months. |
The timing hypothesis pearl. The benefit-risk balance of HRT is most favourable when initiated within 10 years of menopause or before age 60 — the so-called “window of opportunity”. The Davis Lancet 2022 review and the Cho 2023 Rethinking MHT paper synthesise the ELITE, KEEPS and DOPS data: starting transdermal oestradiol-based HRT in this window is associated with neutral-to-favourable cardiovascular outcomes and well-defined symptomatic benefit. Outside the window, the calculus is more nuanced and individualised; this does not mean “never start late” but rather “counsel the late-starter carefully”.
Embedded knowledge check — HRT regimen
Mini-SBA · 49-year-old woman with migraine with aura wanting HRT
A 49-year-old woman with a 30-year history of migraine with aura presents with disabling night sweats, two-hourly nocturnal awakenings, and low mood for nine months. Her last menstrual period was four months ago. BMI 27 kg/m². BP 124/78. No personal history of VTE, breast cancer, or stroke. She has previously been told that she “cannot have HRT because of the aura”. What is the most appropriate first-line HRT regimen, per BMS 2022?
Correct answer: C. BMS 2022 explicitly clarified that migraine with aura is not a contraindication to transdermal HRT — the venous-thromboembolic and arterial-thrombotic concern is largely confined to oral, ethinyl-oestradiol-containing combined hormonal contraception (FSRH UKMEC 4) and to a lesser extent to oral HRT (option B, where the oral route would be less optimal here). Transdermal oestradiol bypasses first-pass hepatic effect and does not raise VTE risk above background. She is perimenopausal (cycling, just had a period four months ago) so a sequential regimen is appropriate (option C — micronised progesterone 200 mg for 12 days each cycle). Tibolone (D) is licensed only for postmenopausal women with ≥ 12 months amenorrhoea. SSRIs (A) are an option for women who cannot or will not take HRT but are second-line for vasomotor symptoms when HRT is available. Combined hormonal contraception (E) is contraindicated by aura.
The first targeted non-hormonal vasomotor therapy in NHS prescribing
For a long time, women who could not or would not take HRT had only off-licence SSRIs / SNRIs (with limited and inconsistent evidence), gabapentin, clonidine, complementary therapies and CBT to choose between. The 2024 arrival of fezolinetant (Veoza) — a selective neurokinin-3 receptor antagonist — has changed this category. NICE TA1143 recommends fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause in adults for whom hormone replacement therapy is contraindicated or not tolerated. This is the first targeted non-hormonal vasomotor therapy with phase-3 randomised-controlled-trial evidence, NICE economic evaluation, and a defined NHS prescribing position.
Mechanism — restoring KNDy thermoregulatory tone without an oestrogen effect
As detailed in Section 02, the loss of oestradiol negative feedback on KNDy neurons during menopause produces neurokinin-B (NKB) hyperactivity at the median preoptic nucleus, the proximate trigger for the hot flash. Fezolinetant is a selective antagonist of the neurokinin-3 receptor (NK3R) on the KNDy neuron — it blocks NKB binding, restores thermoregulatory tone, and abolishes the vasomotor symptom without any effect on oestrogen receptors anywhere else in the body. The mechanism is targeted, the effect is fast (clinically meaningful within one week, plateau by four), and the side-effect profile is correspondingly narrow.
SKYLIGHT — the phase-3 evidence base
| Trial | Design · population | Headline outcome |
|---|---|---|
| SKYLIGHT 1 (Lederman, Lancet 2023) | Phase 3, double-blind, placebo-controlled · 522 women age 40–65 with moderate-to-severe VMS · 12 weeks blinded then 40 weeks active | Fezolinetant 45 mg reduced moderate-to-severe VMS frequency by ~ 2.55 episodes/day vs placebo at week 12; severity reduction parallel; clinically meaningful from week 1. |
| SKYLIGHT 2 (Johnson, JCEM 2023) | Phase 3, double-blind, placebo-controlled · 484 women · same design | Confirmatory, ~ 2.53 episodes/day reduction at week 12. Sleep-disturbance signal favourable on Patient-Reported Outcomes Measurement Information System (PROMIS) instrument. |
| SKYLIGHT 4 (Neal-Perry, Menopause 2024) | Phase 3 long-term safety study · 1,830 women · 52 weeks of fezolinetant 30 mg, 45 mg, or placebo | Endometrial-safety endpoints met (1 hyperplasia in 30-mg arm; 2 in 45-mg arm; 1 malignancy in 30-mg arm — all within FDA endometrial-safety criteria). Hepatic transaminase rise infrequent and reversible; baseline LFTs and 3-monthly LFTs at first 9 months are NICE-recommended. |
| DAYLIGHT (Schaudig, BMJ 2024) | Phase 3b RCT of fezolinetant in women specifically unsuitable for HRT · 453 women | Magnitude of effect comparable to SKYLIGHT 1 / 2 in the precise population for whom NICE TA1143 endorses use. |
NICE TA1143 — who qualifies, who prescribes, what to monitor
Identify the eligible woman
Adults with moderate-to-severe vasomotor symptoms associated with menopause, where HRT is contraindicated, not tolerated, or — per NICE TA1143 wording — “unsuitable”. Typical scenarios: prior or current oestrogen-receptor-positive breast cancer (with oncology agreement); strong personal history of VTE; severe migraine with aura where transdermal HRT was tried unsuccessfully; declared patient preference against HRT after counselling; or HRT failure in residual VMS.
Pre-treatment baseline
Liver function tests at baseline. Confirm absence of cirrhosis, severe hepatic impairment, end-stage renal disease (eGFR < 30 mL/min/1.73 m²) — fezolinetant is contraindicated in these. Document the VMS frequency / severity for outcome tracking. Counsel on hepatic monitoring requirement.
Initiate fezolinetant 45 mg orally once daily
Single 45 mg dose, taken with or without food, at any time of day; a regular daily time aids adherence. Most women experience clinically meaningful VMS reduction within 1–2 weeks; plateau by weeks 4–8. Continue if effective; review at 12 weeks.
Hepatic monitoring
Repeat LFTs at month 3, month 6 and month 9 of treatment. Stop if ALT or AST > 3× ULN with bilirubin > 2× ULN, or symptoms of hepatic injury. Most transaminase rises are mild and reversible on cessation.
Reassess and continue / discontinue
Annual review of efficacy and side effects. Discontinue if no meaningful response after 12 weeks at full dose. There is no fixed stop-date; continuation is individualised. Confirm with the woman whether to continue indefinitely or reassess with a planned-stop trial if VMS appear to have abated naturally.
The sleep pearl. SKYLIGHT 1 and 2 documented sleep-quality improvements on PROMIS-Sleep Disturbance and PROMIS-Sleep-Related Impairment scales. The mechanism is reduction of nocturnal vasomotor episodes restoring sleep architecture — this is not a primary hypnotic effect (no GABAergic or histaminergic activity). The clinical implication: in a woman whose dominant complaint is night-sweat-related insomnia and who is unsuitable for HRT, fezolinetant addresses both symptoms with one pill rather than the combination of an SSRI plus a hypnotic.
Other non-hormonal options — even-handed summary
| Agent / approach | Evidence summary | Position vs fezolinetant |
|---|---|---|
| SSRIs / SNRIs (venlafaxine, citalopram, escitalopram, paroxetine) | ~ 30–60% reduction in VMS frequency vs placebo; meta-analyses BMJ 2014, Cochrane 2020. Off-licence in UK for VMS (paroxetine licensed for VMS in some jurisdictions). | Reasonable second-line where fezolinetant is contraindicated, declined, or where there is co-existing depression. Avoid paroxetine if patient is on tamoxifen. |
| Gabapentin / pregabalin | Modest VMS reduction; useful where co-existing neuropathic pain, restless legs, or chronic insomnia. | Third-line; sedation common. |
| Clonidine | NICE-listed but small effect size (~ 0.5 fewer episodes/day) and adverse effect profile (rebound hypertension, dry mouth). | Last-line; rarely used now. |
| CBT for menopause | Strong NICE recommendation (NG23) for VMS and mood; structured programmes via NHS Talking Therapies / Women’s Health Hubs. | Use alongside any pharmacological approach; particularly valuable where psychological burden dominates. |
| Lifestyle (cooling, layered clothing, fan, paced respiration, weight loss in obese patients) | Modest effect; high acceptability; no contraindications. | Adjunct to all pharmacological options. |
| Phytoestrogens, black cohosh, red clover, evening primrose oil | Heterogeneous evidence; small effects in some studies, neutral in others; no licensed UK products. | Patient-led use is common; counsel on theoretical hormonal effects in breast-cancer survivors and on lack of regulation. |
| Elinzanetant (NK1 + NK3 dual antagonist) | OASIS 1, 2, 3 phase-3 trials (Pinkerton, JAMA 2024) — comparable VMS reduction to fezolinetant plus enhanced sleep effect. Bayer programme. | Anticipated UK arrival 2026–27; will become a second NK-pathway option for HRT-unsuitable women. |
Embedded knowledge check — fezolinetant pathway
Mini-SBA · 53-year-old woman post-tamoxifen with severe VMS
A 53-year-old woman is two years into adjuvant tamoxifen for ER-positive, node-negative early breast cancer (no chemotherapy required; surgery and radiotherapy completed). Severe vasomotor symptoms have escalated over six months — 14 hot flashes per day, three to four nocturnal episodes severe enough to wake her, and PHQ-9 score 11. Her oncologist has confirmed in writing that systemic HRT is not appropriate. BMI 27, BP 122/76, ALT 24, eGFR 78. She has read about “a new menopause pill” and asks whether it would be suitable. What is the most appropriate first-line non-hormonal pharmacological option, per NICE TA1143?
Correct answer: D. Fezolinetant 45 mg daily is recommended by NICE TA1143 for moderate-to-severe vasomotor symptoms in women for whom HRT is contraindicated or unsuitable. This patient meets the criteria — ER-positive breast cancer on tamoxifen, oncologist confirmation that HRT is inappropriate, and substantial symptom burden. SKYLIGHT and DAYLIGHT data confirm efficacy in exactly this population. Paroxetine (A) is contraindicated alongside tamoxifen — it is a strong CYP2D6 inhibitor and reduces tamoxifen’s active metabolite endoxifen. Black cohosh (B) has heterogeneous evidence and theoretical hormonal effects making it an unsafe choice in breast-cancer survivorship. Clonidine (C) has small effect size and an adverse-effect profile (rebound hypertension, dry mouth) making it last-line. Vaginal oestradiol (E) is for genitourinary syndrome of menopause, not vasomotor symptoms. Baseline LFTs and 3-monthly LFTs at months 3, 6 and 9 are NICE-recommended for fezolinetant.
BSSM 2022, ISSAM 2024, and the TRAVERSE-era cardiovascular conversation
Andropause / TDS sits at the cardiometabolic-genitourinary intersection in men. The BSSM 2022 guideline is the canonical UK reference; the ISSAM 2024 international position and the Endocrine Society 2024 update broadly align. The defining contemporary trial is TRAVERSE (Lincoff, NEJM 2023, n = 5,246) which established cardiovascular non-inferiority of testosterone gel versus placebo for major adverse cardiac events in men with hypogonadism and either pre-existing CVD or high CV risk — but flagged signals for atrial fibrillation, non-fatal arrhythmias, and acute kidney injury that require disclosure and monitoring.
Even-handed UK testosterone-replacement therapy options
| Preparation | Dose · interval · UK product | Position / pearl |
|---|---|---|
| Transdermal gel | Testogel / Tostran / Testavan; 40.5–81 mg daily; apply morning to upper arms / shoulders | BSSM-preferred first-line for ease of titration and reversibility. Avoid skin contact with women and children for 2–4 hours after application; shower / wear shirt. |
| Long-acting intramuscular undecanoate (Nebido) | 1000 mg deep IM at week 0, week 6, then every 10–14 weeks | Convenient; stable trough levels; preferred in patients struggling with daily routines or skin sensitivity. Loading interval is 6 weeks then 10–14 weeks individualised. |
| Short-acting intramuscular enanthate / cypionate (Sustanon 250) | 250 mg IM every 2–3 weeks | Saw-tooth profile produces peaks and troughs; legacy preparation; less commonly first-line now. |
| Buccal tablets (Striant) | 30 mg twice daily mucoadhesive tablet | Specialist; rarely used in UK primary care. |
| Oral testosterone undecanoate (Andriol) | 40 mg capsules; 80–240 mg/day | Variable absorption; little used; not BSSM-preferred. |
| Clomiphene citrate (off-licence) | 25 mg alternate days or daily | Useful in younger men with secondary hypogonadism wanting fertility preservation. Stimulates endogenous LH / FSH and testosterone production. BSSM 2022 endorses; ISSAM 2024 supports. |
| hCG (off-licence) | 1500 IU SC twice or three times weekly | Specialist use; fertility preservation alongside testosterone or as alternative. |
TRAVERSE 2023 — what to tell the patient
TRAVERSE randomised 5,246 men aged 45–80 with hypogonadism (TT < 10.4 nmol/L on two morning samples) and either pre-existing CVD or high CV risk to transdermal 1.62% testosterone gel (titrated to TT 12–26 nmol/L) versus placebo gel for a mean 22 months. The primary 3-point MACE endpoint (CV death, non-fatal MI, non-fatal stroke) was non-inferior between testosterone and placebo (event rates 7.0% vs 7.3%, P < 0.001 for non-inferiority). Cardiovascular reassurance — at the population level — was the headline. However, secondary signals require honest disclosure:
Atrial fibrillation signal
91 cases on testosterone vs 63 on placebo (P = 0.02). Approximately 50% relative excess. Mechanism uncertain — possible erythrocytosis or sympathetic effect. Document baseline rhythm; ask about palpitations at every review; record ECG if symptomatic.
Non-fatal arrhythmias signal
Higher overall rate of any non-fatal arrhythmia in the testosterone arm (P = 0.001). Combined AF + arrhythmia signal is the most clinically actionable TRAVERSE finding.
Acute kidney injury signal
60 vs 40 cases (P = 0.04). Volume / haematocrit-mediated mechanism likely. Check baseline U&Es; recheck at 3 and 12 months; counsel on dehydration and sick-day rules in older men.
Pulmonary embolism signal (also seen)
Numerically higher in testosterone arm but did not reach significance in primary analysis. MHRA UK label retains a VTE caution. Identify men with prior VTE or strong family history; counsel and individualise.
Monitoring schedule
| Timing | What to check | Action thresholds |
|---|---|---|
| Baseline | TT × 2 (morning), SHBG, free T (calculated), LH, FSH, prolactin, PSA, FBC, U&Es, LFTs, lipid profile, HbA1c, BP, BMI, AMS / IIEF-5 score | Establish diagnosis; exclude contraindications; document body composition. |
| 3 months | TT (mid-interval for gel; trough for IM undecanoate), Hb / Hct, PSA, U&Es, BP, symptoms | Target TT mid-normal range; Hct < 0.54; PSA stable; review symptom response. |
| 6 months | As 3 months; consider DEXA if osteoporosis risk | Continue if effective; reconsider if no symptomatic benefit at 6 months. |
| 12 months and annually | TT, Hb / Hct, PSA, lipid profile, HbA1c, BP, BMI, ECG if any AF / arrhythmia symptoms | Long-term safety surveillance. |
| Stop / review | Hct > 0.54, Hb > 180 g/L → pause / venesect; new AF → cardiology review; PSA rise > 1 ng/mL/year or absolute > 4 → urology; persistent ED despite normal TT → re-investigate | Apply BSSM 2022 stopping criteria. |
Embedded knowledge check — andropause / TDS
Mini-SBA · 32-year-old man with secondary hypogonadism wanting children
A 32-year-old man attends with low libido, fatigue, low mood and reduced morning erections for 18 months. He and his partner are trying to conceive (2 years, no pregnancy). BMI 24 kg/m², no medications. Two morning blood tests: TT 6.8 and 7.1 nmol/L; LH 2.4 and 2.6 IU/L (low); FSH 3.0 IU/L (low); prolactin 220 mU/L (normal); semen analysis low normal motility, low normal count. Pituitary MRI normal. What is the most appropriate management?
Correct answer: C. He has secondary (hypogonadotrophic) hypogonadism — low TT with inappropriately low / low-normal LH and FSH suggests central rather than testicular failure. Pituitary MRI is normal so functional hypothalamic-pituitary suppression (idiopathic, lifestyle, medication) or congenital partial hypogonadism is most likely. The critical issue is fertility intent. Exogenous testosterone replacement (A, B) would suppress LH / FSH further, suppressing spermatogenesis and rendering him sub-fertile during treatment — this is the textbook iatrogenic infertility from inappropriate TRT. BSSM 2022 explicitly endorses clomiphene 25 mg alternate-day or daily as the fertility-preserving alternative — it raises endogenous LH / FSH and stimulates intra-testicular testosterone and spermatogenesis. ISSAM 2024 aligns. Reassurance (D) ignores symptoms and infertility. Surgical sperm retrieval (E) is premature without optimising the hormonal axis first. He should be referred to a combined andrology / fertility service for shared management.
Where the standard menopause and andropause ladders require deliberate adaptation
Four populations consistently dominate referrals and disproportionately drive complaints: women with migraine with aura, ER-positive breast cancer survivors, women with premature ovarian insufficiency, and perimenopausal women requiring contraception. ADHD-perimenopause crossover is the emerging fifth.
Migraine with aura on HRT
BMS 2022 joint position: migraine with aura is not a contraindication to transdermal HRT. Aura on combined hormonal contraception remains FSRH UKMEC 4 — stop COC immediately. Aura on oral oestrogen-containing HRT — switch to transdermal. New aura aged > 50 — investigate per NICE NG150 SNNOOP10. Migraine frequency often falls on stable transdermal oestradiol; document baseline migraine diary.
ER-positive breast cancer survivors
NICE NG215 / BMS 2024: systemic HRT generally avoided. Fezolinetant (TA1143) is the targeted first-line for moderate-to-severe VMS in this group, with oncology agreement. Vaginal oestradiol for GSM is generally safe in MDT-agreed cases (low systemic absorption). Avoid paroxetine if on tamoxifen (CYP2D6 inhibition reduces endoxifen). CBT and lifestyle alongside.
Premature ovarian insufficiency (POI)
Davis Lancet 2024 Commission · ESHRE 2024: diagnose by FSH > 25 IU/L on two occasions ≥ 4 weeks apart with oligo / amenorrhoea ≥ 4 months in women < 40. Initiate HRT (or COC if patient prefers) and continue at least until average natural menopause (~ 51 y). Higher oestrogen doses required (e.g. 100 microgram patch). Bone density, fertility, autoimmune screen, karyotype, fragile-X if < 30 y.
Perimenopausal contraception
FSRH 2023 / UKMEC: contraception required until age 55 (LARC / barrier) or until 12 months amenorrhoea (over 50) / 24 months (under 50). Common pathways: 52 mg LNG-IUS for HMB plus oestrogen-only HRT; progestogen-only pill alongside HRT; switch to transdermal HRT in migraine + aura context. The COC may be continued to age 50 in healthy non-smokers without aura, then transition.
ADHD and perimenopause — the emerging crossover. A growing literature identifies that perimenopausal oestradiol decline unmasks or worsens previously compensated ADHD symptoms, particularly attention, working memory, and executive function (Camara et al, 2024; Roberts et al, 2025). The clinical implication is to consider ADHD assessment in women presenting with new perimenopausal cognitive symptoms, particularly those who report childhood symptoms; and to consider that stimulant titration may need adjustment as oestradiol falls. HRT itself improves working memory and attention modestly in controlled studies and should be optimised before stimulant titration.
Bone, brain, cardiovascular, and the genitourinary syndrome of menopause
Most women survive menopause by three decades. The four long-term domains in which oestradiol deprivation has measurable, modifiable consequences are bone, brain, cardiovascular, and genitourinary. Each is now a discrete sub-field with its own evidence base, its own NICE guidance, and its own primary-care decision tree.
| Domain | What changes at menopause | Primary-care actions |
|---|---|---|
| Bone (NICE NG142, NOGG 2021) | Trabecular bone loss accelerates 1–2%/year for 5–7 years post-menopause; fracture risk rises particularly at vertebra and wrist. | FRAX or QFracture at age 50 (or earlier if risk factors); DEXA if FRAX intermediate / high; HRT first-line for prevention in symptomatic women within window of opportunity; bisphosphonate (alendronate, risedronate, zoledronate) or denosumab for established osteoporosis; calcium, vitamin D, weight-bearing exercise. |
| Brain & cognition (Mosconi 2021; CW Meta-Analysis 2023) | Hot-flash-mediated sleep disruption; transient working-memory decline in transition; possible long-term Alzheimer risk modulation with timing-dependent HRT use. | Validate symptoms — “brain fog” is real not imagined. Optimise sleep via VMS control. Consider HRT within window for cognitive domain symptoms. Screen for treatable contributors (thyroid, B12, depression, OSA). |
| Cardiovascular (Davis Lancet 2024 · Cho 2023 · Ravindran-Varma 2026) | ApoB rises by ~ 10–15%; Lp(a) shifts; HDL functionality declines; visceral adiposity; insulin resistance; BP rises; risk of MI rises postmenopause. | Lipid profile + ApoB at age 50 and around natural menopause; QRISK3 / SCORE2; transdermal HRT preferred where any CV risk; statin where indicated; SGLT2i / GLP-1 RA per DCRM principles where T2DM / CKD / HF develop. |
| Genitourinary syndrome (GSM) (BMS 2024 · IUGA-NAMS 2014) | Vulvovaginal atrophy, dryness, dyspareunia, urinary urgency, recurrent UTI. Affects ~ 50% of postmenopausal women; often progressive; under-reported. | Vaginal oestrogens (estriol cream, oestradiol vaginal tablets, oestradiol-releasing ring) — long-term, low systemic absorption, no progestogen needed. Vaginal moisturisers / lubricants. Continue indefinitely if effective. Generally safe in breast-cancer survivors after MDT discussion (NG215). |
The Ravindran-Varma 2026 message. The cardiometabolic shift at menopause is patterned, predictable, and modifiable — but only if measured. Add ApoB and Lp(a) to the routine peri-menopausal lipid profile; document baseline waist circumference; record QRISK3 and re-run it at age 60 with the new menopausal dataset. Most UK practice still relies on a 50-year-old fasting lipid screen and re-runs only at trigger events. The CAS position is that menopause itself is the trigger event.
Myth-busting — what the evidence does and does not say about HRT and longevity
Four questions dominate patient and clinician debate about HRT. Each has a confident-sounding answer in popular media; each has a more nuanced answer in the evidence; and on each one no international body — UK, USA, Europe, or Australia — has issued a categorical conclusion. The CAS position is that this is an area of legitimate clinical equipoise where the prescriber’s job is to summarise the evidence honestly, not to over-promise or to dismiss.
Does HRT extend life?
Short answer. No clear all-cause mortality benefit; possibly a cardiovascular-mortality signal in younger initiators. The Manson et al JAMA 2017 18-year follow-up of the WHI trials reported no significant difference in all-cause, cardiovascular, or total cancer mortality between HRT and placebo over ~ 18 years of cumulative follow-up — neither for combined oestrogen plus medroxyprogesterone (CEE+MPA, median 5.6 years exposure) nor for unopposed conjugated equine oestrogen (CEE, median 7.2 years). Subsequent meta-regressions (Salpeter 2018, Lobo 2022) detect a coronary-heart-disease and total-mortality signal favouring HRT initiation in women under 60 or within 10 years of menopause. The honest counselling line is “HRT is a quality-of-life therapy with neutral mortality effect at the population level, with possible cardiovascular benefit in younger initiators.”
Cardioprotection & the timing hypothesis
Short answer. Probable benefit in younger initiators; harm or neutrality in older initiators. The timing hypothesis — Manson, Hodis, Mendelsohn — holds that HRT’s cardiovascular effect depends on when it is started relative to menopause. ELITE (Hodis 2016 NEJM) showed reduced subclinical atherosclerosis progression in women < 6 years from menopause but no benefit in those > 10 years out. KEEPS, DOPS and the WHI age-stratified re-analysis are concordant. The IMS, NAMS, BMS, ESC women’s CV 2023 and AHA all acknowledge the timing hypothesis but stop short of recommending HRT for primary cardiovascular prevention. The CAS framing is that cardiovascular benefit is plausible but unproven as an indication on its own — symptom relief in the right window is the appropriate indication.
Does HRT prevent dementia?
Short answer. Equivocal. The Lancet Healthy Longevity 2025 systematic review and meta-analysis concluded that menopause hormone therapy use was associated with neither an increased nor a decreased risk of dementia overall. WHIMS (Shumaker 2003) showed an excess dementia signal when HRT was initiated at age ≥ 65 (HR 2.05 for combined therapy). KEEPS-Continuation (2023) showed no cognitive benefit at 10 years. Mosconi’s neuroimaging work and several observational cohorts suggest possible benefit when initiated peri-menopausally, but no randomised trial has met a dementia-prevention endpoint. The CAS position is that HRT should not be initiated to prevent dementia; women already on HRT for VMS need not stop on dementia-prevention grounds.
Quantified additional risk over 5 years
Short answer. Combined HRT adds approximately 4–10 extra cases per 1,000 women aged 50–59 over 5 years; oestrogen-only HRT is neutral or slightly protective. The detailed quantification per the NICE NG23 / BMS 2024 decision aid for women starting HRT under age 55 with < 5 years duration is in the table below. Counsel using absolute not relative risk; the headline relative-risk figures (often quoted as “30% increase”) make the increment sound much larger than the absolute change of ~ 4–10 in a thousand.
Quantified 5-year additional breast cancer cases per 1,000 women aged 50–59
Figures below are drawn from the NICE NG23 decision aid (October 2019, updated 2024), the British Menopause Society 2024 / 2025 risk infographic, the Beral Collaborative reanalysis (Lancet 2019) and the QResearch / CPRD nested case-control analysis (Vinogradova BMJ 2020). All assume initiation under age 55 and ≤ 5 years duration; effect sizes attenuate after cessation but persist for at least 5 years post-stop.
| Population | Breast cancer cases per 1,000 women over 5 years | Increment vs background |
|---|---|---|
| Background — UK women aged 50–59, no HRT | ~23 per 1,000 | (reference) |
| Oestrogen-only HRT (post-hysterectomy; CEE arm of WHI 2002) | ~20–23 per 1,000 | −3 to neutral · no clinically relevant excess |
| Tibolone (livial), 5 years postmenopausal | ~24 per 1,000 | +1 per 1,000 |
| Combined sequential HRT (cyclical progestogen ≥ 12 days/month) | ~27 per 1,000 | +4 per 1,000 (NICE NG23 figure) |
| Combined continuous HRT (daily progestogen) | ~31 per 1,000 | +8 per 1,000 (NICE NG23) — BMS 2024 cites “8–10 extra cases per 1,000” |
Counselling pearls. (1) Compare to lifestyle. Two units of alcohol per day adds approximately 5 extra breast cancer cases per 1,000 over 5 years — comparable to combined sequential HRT. Sustained obesity (BMI ≥ 30) adds 25–30 extra cases per 1,000 over the same period — much larger than HRT. Patients are usually unaware of this comparison. (2) The progestogen drives most of the signal. Oestrogen-only HRT is neutral or slightly protective; the breast-cancer increment relates to the progestogen, with micronised progesterone showing a smaller signal than synthetic progestogens in the E3N French cohort. (3) Risk attenuates on cessation. The Beral collaborative re-analysis (Lancet 2019) showed persistence at 5 years post-stop but progressive attenuation thereafter. (4) The 5–10-year risk window matters. Initiating HRT under 55 with < 5 years duration is the lowest-risk profile; the calculus changes for longer durations or older initiators. (5) Family history alters the conversation. Strong family history of premenopausal breast cancer warrants tighter counselling and consideration of genetic referral (NICE NG14).
The honest summary for the consultation. “Combined HRT, taken for 5 years starting in your early 50s, would add about 4–10 extra cases of breast cancer per 1,000 women like you over those 5 years. Two glasses of wine a day for the same 5 years would add about 5 cases per 1,000. Carrying significant excess weight for those 5 years would add 25–30. Oestrogen alone, if you have had a hysterectomy, has no convincing increase. The decision is yours; my role is to give you the absolute numbers in context.”
What is happening in the field 2026–2028
The non-hormonal vasomotor pipeline is the most active area. Newer NK-pathway antagonists, dual NK1+NK3 mechanism agents, neurosteroid modulators, and selective oestrogen-receptor modulators with improved breast and uterine profiles are all in late-phase trials. The andropause pipeline is comparatively quieter but a long-acting oral testosterone undecanoate (Tlando, Jatenzo) and SARMs in development warrant attention.
| Agent | Mechanism · trial · indication | Anticipated UK arrival |
|---|---|---|
| Elinzanetant (Bayer) | Dual NK1 + NK3 receptor antagonist · OASIS 1, 2, 3 (Pinkerton, JAMA 2024) · moderate-severe VMS | 2026–27 anticipated EMA / NICE submission |
| NT-814 / similar NK3 antagonists | Selective NK3 antagonist · phase 2 / 3 · VMS | 2027–28 |
| Bazedoxifene + CEE (Duavive) | Tissue-selective oestrogen complex (TSEC) · already UK-licensed but underused; reduced breast tissue density signal · oestrogen + endometrial protection without progestogen | UK-licensed; widening clinical adoption |
| Selective oestrogen-receptor modulators (next generation) | Reduced VMS / improved breast / favourable bone profile; lasofoxifene, oral relugolix combinations | 2028+ |
| Neurosteroid modulators | Allopregnanolone analogues for perimenopausal mood; emerging programme | 2028+ early-stage |
| SARMs (selective androgen receptor modulators) | Tissue-selective; potential fertility-sparing TRT · early phase | Long-term horizon |
| Long-acting oral testosterone undecanoate (Tlando, Jatenzo) | Twice-daily oral; alternative to gel / IM · US-licensed | 2026–27 anticipated UK availability |
| Personalised dosing — pharmacogenomics | CYP variants modify oestradiol metabolism; emerging clinical-grade pharmacogenomic panels | Research domain, 2028+ |
Expert voices — the menopause community on what comes next
Quotations kept under fifteen verbatim words per source for academic-fair-use compliance; longer commentary is paraphrased.
On POI & midlife
Davis (Lancet 2024 POI Commission) characterises POI as “under-recognised, under-treated”. The CAS reading: the diagnosis is biochemical, the treatment is HRT (or COC), and continuation until average menopause age is the standard of care.
On IMS 2025
Panay (IMS 2025 recommendations) frames the contemporary task as “individualised, evidence-based, woman-centred”. The CAS reading: the IMS 2025 position aligns transdermal-first thinking, micronised progesterone preference, and continuation without arbitrary stop dates.
On testosterone deficiency
Hackett (BSSM 2022) underlines that TDS is “a clinical diagnosis with biochemical confirmation”. The CAS reading: do not chase a magic number, treat the symptomatic man whose biochemistry confirms low testosterone, and use the BSSM action levels.
On TRAVERSE
Lincoff (NEJM 2023) summarised TRAVERSE as showing that testosterone replacement was “noninferior to placebo” for major adverse cardiac events, with caveats about AF, AKI and arrhythmia signals. The CAS reading: cardiovascular reassurance with disclosure.
On the timing hypothesis
Manson’s body of work re-affirms that initiating HRT “within ten years of menopause” shifts the cardiovascular calculus favourably. The CAS reading: counsel the late-starter carefully, and start the early-perimenopausal woman without artificial age cutoffs.
On precision menopause
Varma (Ravindran-Varma, InnovAiT 2026) argues for “precision menopause treatment” integrating cardiometabolic measurement at the time of transition. The CAS reading: ApoB, Lp(a), waist circumference and QRISK3 belong in the perimenopausal review, not deferred to age 60.
Professor-level multimorbidity — the patients referred to a specialist menopause / andropause clinic
Three cases sit deliberately above MRCGP-AKT difficulty. Each requires synthesis across at least two of the four CAS units and at least two guideline frameworks. Work each case staged decision-by-staged decision. Model answers cite specific guidelines.
59-year-old woman with heavy unscheduled bleeding on long-standing HRT
A 59-year-old woman attends with five weeks of progressively heavier vaginal bleeding, now requiring pad use day and night. She has been on transdermal oestradiol 75 microgram patch for 7 years and has had a 52 mg LNG-IUS in situ throughout (last replaced 7 years ago for combined HRT and contraception). BMI 42 kg/m². T2DM 8 years on metformin and dapagliflozin. No PCOS history; no Lynch / Cowden syndrome but father had colorectal cancer aged 71. Cervical screening up to date. Last TVS 4 years ago — normal. Pelvic exam unremarkable; speculum normal cervix; bimanual non-tender. Hb 102 g/L (down from 132 a year ago); ferritin 8 microgram/L. Apply the BMS-RCOG 2024 pathway and decide.
Q1 · Risk-stratify her for endometrial cancer and decide which pathway she enters.
She enters the urgent-suspicion-of-cancer pathway. Two major factors are present: (a) BMI ≥ 40; and (b) the LNG-IUS is past its 5-year HRT-licensed life — the disproportionate progestogen-to-oestrogen exposure of an “expired” LNG-IUS is explicitly listed as a major risk factor in the 2024 guideline. Either alone would qualify her for USCP. She also has minor risk factors (T2DM, BMI 30–39 — already counted toward the major BMI ≥ 40, so don’t double-count, and the family history of colorectal cancer at 71 is not Lynch-syndrome-defining but warrants documentation). The bleeding is heavy and persistent. She has anaemia. Refer under USCP within 2 weeks per NICE NG12 / BMS-RCOG 2024.
Anchor. Manley et al 2024 §2 (Risk factors); GIRFT Summary Guide June 2024; NICE NG12 (suspected cancer).
Q2 · While she is awaiting her USCP appointment, what immediate primary-care actions are required?
Five immediate actions. (1) Iron-deficiency anaemia — initiate oral iron (ferrous fumarate 210 mg twice daily) or, given Hb 102 and likely ongoing losses, consider IV iron via the practice or community service; check folate and B12. (2) Replace the expired 52 mg LNG-IUS with a new device — ideally at the gynaecology USCP attendance, or in primary care if she will tolerate. Document the previous device removal and replacement. (3) Continue transdermal oestradiol — withholding HRT is not required and may worsen symptoms. The decision on continuation is for after the USCP workup. (4) Review her DCRM regimen — confirm dapagliflozin sick-day rules, optimise glycaemia (HbA1c, BP, lipids — relevant given the cardiometabolic shift). (5) Document the consultation, the USCP referral, the immediate management, and the safety-net.
Anchor. NICE NG8 (acute IDA in adults); BMS-RCOG 2024 §5 (Adjusting HRT to reduce unscheduled bleeding); NICE NG12.
Q3 · TVS at the USCP clinic shows ET 11 mm with a focal area of irregular thickening; outpatient hysteroscopy + biopsy confirms simple endometrial hyperplasia without atypia. The gynaecology team have replaced her LNG-IUS. They write to ask your opinion on continuing systemic HRT. What is your recommendation?
Reasonable to continue HRT with optimised endometrial protection. Simple hyperplasia without atypia carries a low (~ 1–3%) risk of progression to endometrial cancer over 10 years, and in this woman the underlying driver is likely the expired LNG-IUS combined with her BMI rather than the systemic oestradiol per se. The new LNG-IUS provides robust endometrial protection. Consider also (a) adding an oral progestogen (micronised progesterone 100 mg) for the first 3–6 months until full LNG-IUS effect re-establishes, or (b) switching from continuous transdermal patch to a lower-dose continuous regimen if VMS allow. (c) Weight optimisation is a high-value lever — a referral to NHS Tier-3 weight-management or specialist pathway is appropriate given BMI 42 and T2DM. Cancer pathway: 6-monthly TVS for 1–2 years; biopsy if any further bleeding. Multidisciplinary review at 12 months. Re-counsel on individualised risk vs benefit; some women prefer to stop HRT. The decision must be hers and documented.
Anchor. RCOG / BMS endometrial hyperplasia guideline (Green-top 67, updated 2023); BMS-RCOG 2024 §5 + Appendix 3; NICE NG23.
52-year-old woman, 18 months post-diagnosis, with debilitating VMS and insomnia
A 52-year-old teacher had stage I, ER+/PR+/HER2-negative early breast cancer 18 months ago, treated with wide local excision, sentinel-node biopsy (negative), radiotherapy, and now adjuvant tamoxifen 20 mg daily. Severe vasomotor symptoms have escalated over 12 months — 18 hot flashes per day, six nocturnal awakenings, PHQ-9 score 14, GAD-7 score 12, daytime functional impairment. She has tried venlafaxine 75 mg modified-release (modest 30% VMS reduction, GI side effects led to dose reduction to 37.5 mg) and gabapentin 300 mg three times daily (sedation, ineffective). Her oncologist has confirmed in writing that systemic HRT is not appropriate. BMI 26 kg/m². BP 118/74. ALT 22, eGFR 78. Build her a contemporary management plan.
Q1 · What is the first-line pharmacological step now, and why does it match her exactly?
Initiate fezolinetant 45 mg orally once daily. She fits NICE TA1143 precisely — moderate-to-severe VMS with HRT contraindicated, on first-line non-hormonal therapy already failing or sub-optimally tolerated. SKYLIGHT 1 / 2 / 4 and DAYLIGHT (Schaudig BMJ 2024) demonstrated efficacy in exactly this clinical situation, including the breast-cancer-survivor sub-population. Stop venlafaxine and gabapentin in stepwise fashion (avoid abrupt withdrawal). Baseline LFTs are normal — proceed. Recheck LFTs at month 3, month 6, month 9. Counsel on expected effect within 1–2 weeks plateauing at 4–8 weeks.
Avoid paroxetine. If anyone re-suggests an SSRI, paroxetine is contraindicated alongside tamoxifen — strong CYP2D6 inhibitor, reduces endoxifen, theoretical anti-tumour effect. Citalopram, escitalopram, venlafaxine are CYP2D6-neutral or weak.
Anchor. NICE TA1143; SKYLIGHT 1/2/4; DAYLIGHT (BMJ 2024); MHRA paroxetine-tamoxifen interaction; NICE NG215 (cancer in adults & older people: menopause).
Q2 · How do you address her insomnia, mood and anxiety symptoms alongside fezolinetant?
Fezolinetant’s secondary sleep benefit is real but indirect. Restoration of nocturnal thermoregulatory tone reduces awakenings and improves sleep architecture. SKYLIGHT 1 / 2 documented this on PROMIS-Sleep scales. Many women therefore experience sleep recovery within 2–4 weeks of fezolinetant initiation without a primary hypnotic.
For PHQ-9 14 and GAD-7 12, follow NICE NG222 (depression) and NG134 (anxiety) — use a CYP2D6-neutral SSRI (sertraline, escitalopram) if pharmacological therapy is needed alongside fezolinetant, and refer to NHS Talking Therapies for high-intensity CBT. Consider menopause-specific CBT (Hunter / Smith protocol) — strong NICE NG23 endorsement and useful even where pharmacological response is good.
Document a 4-week and 12-week reassessment of all three symptom dimensions (VMS, mood, anxiety). Many women find that VMS resolution is sufficient to lift mood and anxiety scores back into normal range — re-test before adding a second pharmacological agent.
Anchor. NICE NG222, NG134, NG23; SKYLIGHT 1 / 2 sleep sub-analysis (Lederman, Lancet 2023; Johnson, JCEM 2023).
Q3 · She also reports vaginal dryness and dyspareunia. What is your approach, given her ER-positive history?
Vaginal oestrogen is generally safe in ER-positive breast-cancer survivors after MDT discussion. NICE NG215 and BMS 2024 endorse low-dose vaginal oestradiol (Vagifem 10 microgram tablets) or estriol cream (Ovestin) for genitourinary syndrome of menopause in this population, recognising minimal systemic absorption. Discuss with her oncologist; document the agreement; counsel her on the rationale (local effect, no systemic oestradiol rise of clinical relevance). If vaginal oestrogen is declined or contraindicated, vaginal moisturisers (Replens, Hyalofemme) and lubricants are first-line; vaginal DHEA (prasterone, Intrarosa — UK availability variable) is an alternative. Pelvic-floor physiotherapy referral if dyspareunia has secondary muscle component.
Anchor. NICE NG215; BMS 2024 GSM position; IUGA-NAMS 2014 GSM consensus.
36-year-old woman with POI, Hashimoto’s and a five-year fertility plan
A 36-year-old NHS pharmacist presents with 6 months of secondary amenorrhoea, vasomotor symptoms, low mood, and dyspareunia. Two morning FSH samples 4 weeks apart: 38 and 42 IU/L. Oestradiol < 50 pmol/L. AMH undetectable. Karyotype 46,XX. Fragile X premutation negative. Anti-thyroid peroxidase antibodies positive; TSH 4.8 mIU/L; T4 14 pmol/L (low-normal) — early Hashimoto’s. Adrenal antibody screen negative. BMI 23 kg/m², BP 116/72. Family history: mother had natural menopause aged 42 (early menopause). She and her partner would like to try for pregnancy within five years. Build her a comprehensive plan.
Q1 · What is the diagnosis, and what does the Davis Lancet 2024 Commission framework recommend for hormone replacement?
Premature ovarian insufficiency (POI), confirmed. ESHRE 2024 / Davis Lancet 2024 Commission criteria: oligo / amenorrhoea ≥ 4 months in a woman < 40 plus FSH > 25 IU/L on two occasions ≥ 4 weeks apart. Karyotype, fragile X premutation, autoimmune screen, and adrenal antibody screen complete the workup — done. The autoimmune cluster (early Hashimoto’s) is consistent with autoimmune-related POI; document and screen annually for adrenal insufficiency.
Initiate HRT urgently — to be continued at least until age 51 (average natural menopause). POI is not an indication for cautious dosing; she requires physiological replacement, not symptom-control dosing. Transdermal oestradiol 100 microgram patch (or higher if symptoms unresolved) plus micronised progesterone 100 mg continuous (or 200 mg sequential 12 days/cycle if she prefers monthly bleeds for conception monitoring) — or 52 mg LNG-IUS if she prefers. Counsel that this is replacement of a normal physiological hormone, not pharmacological treatment.
Combined oral contraceptive is an alternative if she prefers — provides oestrogen and acts as contraception (POI does not eliminate spontaneous ovulation; ~ 5% pregnancy rate has been described). However, transdermal HRT + barrier or LNG-IUS for contraception is the BMS / Davis-preferred long-term option.
Anchor. Davis SR et al, Lancet 2024 POI Commission; ESHRE 2024 POI guideline; BMS 2024.
Q2 · How do you address her fertility intent over five years?
Refer to a specialist reproductive endocrinology / fertility service early. Spontaneous pregnancy occurs in ~ 5–10% of women with POI; this is unpredictable and rarely sustainable as a fertility plan. The contemporary options are (a) donor oocyte IVF — high success rate; available within NHS in some ICBs (variable, often deprived areas have access; high-deprivation patients more likely to have access than middle-class patients due to means-testing nuances) but more often privately funded; (b) oocyte cryopreservation from fertile relatives — limited utility but available; (c) egg-sharing schemes; (d) adoption. Counsel on the realistic spontaneous-conception probability without offering false hope.
HRT does not impair the chance of spontaneous ovulation but does provide cardiometabolic and bone protection during the wait. Use barrier contraception alongside if pregnancy is not yet wanted.
Anchor. Davis Lancet 2024 POI Commission; ESHRE 2024; HFEA UK fertility services.
Q3 · What long-term cardiometabolic and bone monitoring does she need, and what is the autoimmune surveillance schedule?
Cardiometabolic. Lipid profile + ApoB + Lp(a) once at baseline (Lp(a) once-in-life). Repeat lipid profile 3 years; QRISK3 at age 40 then every 5 years. Watch for accelerated cardiometabolic shift — POI confers double the cardiovascular event rate of women with natural menopause if untreated.
Bone. DEXA at baseline; repeat at 5-year intervals. Calcium / vitamin D supplementation guided by serum 25-OH-vitamin-D. Weight-bearing exercise.
Thyroid surveillance. TFT every 6–12 months given autoimmune POI + TPO antibody positivity + TSH already 4.8. Treat with levothyroxine when symptomatic or TSH consistently > 10.
Adrenal surveillance. Annual symptom screen for adrenal insufficiency (autoimmune polyglandular syndrome type II); consider 21-hydroxylase antibody and morning cortisol if symptomatic — early autoimmune Addisonian features (weight loss, hyperpigmentation, hyponatraemia) require urgent endocrinology.
Mental health. Active screening — diagnosis-related psychological burden is high; offer NHS Talking Therapies referral and signposting to peer support (Daisy Network).
Anchor. Davis Lancet 2024; ESHRE 2024; NICE NG23; BMS 2024; ESC 2023 women’s CV; Daisy Network.
Single-best-answer assessment across the four pillars — alongside the four embedded in-section knowledge checks
Ten items in clinical-vignette format pitched at synoptic-CAS level (above MRCGP-AKT). Each item has a single best answer and four defensible-but-wrong distractors with explicit guideline citation in the rationale. The ten items below are in addition to the four embedded mini-SBAs at the end of the bleeding pathway (Section 05), HRT regimen (Section 06), fezolinetant pathway (Section 07), and andropause / TDS (Section 08) sections — fourteen items in total across the module.
How to use this integrative check. Work through all ten items in one sitting before opening the rationales — this trains the synoptic-style synthesis the CAS assessments require. Aim for ≥ 7 / 10 across the integrative check, plus ≥ 3 / 4 across the embedded mini-SBAs. The full sample Menopause & Andropause Synoptic Self-Assessment is the 20-item instrument designed for revision and self-assessment after the module.
SBA 1 · Diagnosis · 47-year-old woman with classic vasomotor symptoms
A 47-year-old woman attends with 8 months of hot flashes (8–10 daytime episodes), night sweats, sleep disturbance, low mood and irregular periods (last period 6 weeks ago). BMI 27 kg/m². No personal or family history of breast or endometrial cancer. No medications. Per NICE NG23 (2024 update), what is the most appropriate next step?
Correct answer: A. NICE NG23 (2024 update) is unambiguous: in women aged 45 or over presenting with menopausal-pattern symptoms, the diagnosis is clinical and FSH testing is not indicated. Testing FSH (B) adds cost, delays treatment, often returns “normal” results that mislead. Reassurance (C) ignores burden. Gynaecology referral (D) is unnecessary at this point. SSRI first-line (E) inverts NG23’s clear position that HRT is first-line for VMS in the absence of contraindication.
SBA 2 · Bleeding pathway · 62-year-old woman, 7 days of bleeding 14 months after starting ccHRT
A 62-year-old woman attends with 7 days of moderate vaginal bleeding. She started continuous combined HRT (transdermal oestradiol 50 microgram + micronised progesterone 100 mg daily) 14 months ago for severe vasomotor symptoms. BMI 31 kg/m². No diabetes, no PCOS history. Cervical screening up to date. No personal / family history of endometrial / colorectal / ovarian cancer. Per the BMS-RCOG 2024 pathway, what is the next step?
Correct answer: B. The bleeding has occurred > 6 months after initiation of HRT — per the BMS-RCOG 2024 pathway, this triggers urgent transvaginal ultrasound within 6 weeks. She does not have a major risk factor (BMI 31 is a minor factor) or three minor risk factors, so the urgent-suspicion-of-cancer pathway (C) is not yet activated. ccHRT TVS threshold is 4 mm — > 4 mm escalates to USCP at that point. Optimising HRT (A) applies only to bleeding within the first 6 months in low-risk women. Stopping HRT (D) does not address the diagnostic question. Reassurance alone (E) is incorrect — late bleeding requires investigation.
SBA 3 · HRT regimen · 50-year-old woman, BMI 33, choosing first HRT
A 50-year-old woman with BMI 33 kg/m² is reviewed for moderate-severe vasomotor symptoms. Last menstrual period 13 months ago. BP 130/80. No personal / family history of VTE or breast cancer. Cervical screening up to date. What is the most appropriate first-line HRT regimen?
Correct answer: E. She is postmenopausal (≥ 12 months amenorrhoea), so a continuous combined regimen is appropriate. BMI 33 raises VTE risk on oral oestrogen — NICE NG23 / BMS 2024 endorse transdermal oestradiol as first-line wherever VTE-risk modifiers exist. Micronised progesterone (Utrogestan) is the preferred body-identical, low-VTE, low-breast-signal progestogen at 100 mg continuous. Oral oestrogen (A, B) carries 2–4× background VTE risk. Tibolone (C) is an option but not first-line. Vaginal oestrogen alone (D) is for genitourinary symptoms, not vasomotor.
SBA 4 · Migraine with aura · 45-year-old perimenopausal woman
A 45-year-old woman with longstanding migraine with aura attends with severe vasomotor symptoms. She is on the combined oral contraceptive (microgynon 30) for cycle control and migraine prevention. She had aura twice in the last month, more frequent than her usual baseline (one or two per year). BMI 26, BP 122/76. Last period 2 months ago. What is the most appropriate management?
Correct answer: E. New or worsening aura on combined hormonal contraception is FSRH UKMEC 4 (unacceptable risk) — stop COC immediately. Transdermal HRT is not contraindicated by aura (BMS 2022) — switch to a sequential transdermal regimen (still cycling at 45 with last period 2 months ago). Continuing the COC (A, C) ignores the UKMEC 4. Switching to oral HRT (D) carries the same arterial-thrombotic concern as the COC. POP plus transdermal HRT (B) is reasonable but not the first-best step — sequential HRT alone covers both VMS and contraception adequately if cycle control resumes; otherwise add LNG-IUS or barrier.
SBA 5 · Breast cancer survivor · 54-year-old on tamoxifen with severe VMS
A 54-year-old woman is on adjuvant tamoxifen for ER-positive early breast cancer. She has 16 hot flashes per day, 4 nocturnal episodes, sleep collapse and PHQ-9 score 12. Her oncologist confirms in writing that systemic HRT is not appropriate. BMI 25, ALT 22, eGFR 80. Which is the most appropriate first-line non-hormonal pharmacological option, per NICE TA1143?
Correct answer: D. NICE TA1143 recommends fezolinetant for moderate-to-severe VMS in adults for whom HRT is contraindicated or unsuitable — the breast-cancer survivor on tamoxifen meets this exactly. SKYLIGHT and DAYLIGHT trials confirm efficacy in this population. Paroxetine (A) is contraindicated alongside tamoxifen — strong CYP2D6 inhibitor reducing endoxifen. Clonidine (B) has small effect size and adverse-effect profile. Tibolone (C) showed increased breast-cancer recurrence in the LIBERATE trial and is contraindicated post-breast cancer. Black cohosh (E) has heterogeneous evidence and theoretical hormonal effects making it unsafe in this context.
SBA 6 · POI workup · 33-year-old with secondary amenorrhoea
A 33-year-old woman attends with 5 months of secondary amenorrhoea, vasomotor symptoms, and dyspareunia. Pregnancy test negative. Two FSH levels 4 weeks apart: 36 and 41 IU/L. Oestradiol < 50 pmol/L. AMH undetectable. What is the next set of investigations she requires before starting HRT?
Correct answer: C. ESHRE 2024 / Davis Lancet 2024 POI Commission outline the full diagnostic workup once the biochemical diagnosis is met. Karyotype (Turner-mosaic, 46,XY), fragile X premutation (FMR1), autoimmune screen (TPO antibodies for Hashimoto’s, 21-hydroxylase antibodies for autoimmune Addisonian risk), DEXA for bone-health baseline, and a cardiometabolic baseline (lipid profile + ApoB + Lp(a) once-in-life) are all part of the workup. HRT initiation should not be delayed by these tests — start it concurrently. Pelvic imaging (A, D) is not part of POI workup. Repeat FSH (B) is unnecessary if two values already confirm the diagnosis. Oncology referral (E) is inappropriate.
SBA 7 · Andropause · 58-year-old man with low energy and ED
A 58-year-old man attends with 18 months of low libido, erectile dysfunction (responds partially to sildenafil 100 mg), reduced morning erections, fatigue and low mood. Two morning blood samples 2 weeks apart, both at 09:00: total testosterone 7.4 and 7.8 nmol/L; SHBG 28 nmol/L; calculated free T 165 pmol/L (low); LH 6 and 7 IU/L (normal); FSH 5 IU/L. PSA 1.2 ng/mL. Hb 148 g/L. Hct 0.42. BMI 28, BP 132/82, HbA1c 49 mmol/mol. Family complete. What is the most appropriate management, per BSSM 2022?
Correct answer: A. Total testosterone < 8 nmol/L on two morning samples confirms BSSM 2022 testosterone deficiency. Symptoms are present (sexual + non-sexual). LH is in the upper-normal range with low FSH — primary testicular failure with appropriate gonadotrophin compensation. He has no contraindications: PSA 1.2 (low), Hb 148, Hct 0.42 (acceptable for initiation; threshold 0.54 for stopping). Family complete so fertility-preservation strategies (E — clomiphene) are not required. Watchful waiting (B, C) is inappropriate where confirmed TDS plus symptoms are present. Urology referral (D) is unnecessary unless PSA is rising.
SBA 8 · TRAVERSE follow-up · TRT recipient develops palpitations
A 64-year-old man started transdermal testosterone gel 8 months ago for confirmed testosterone deficiency. He has had good symptomatic response. He attends with new-onset palpitations and intermittent fluttering, particularly at rest, for 3 weeks. He denies chest pain or syncope. Pulse 86 irregular. ECG shows atrial fibrillation. eGFR 72. What is the most appropriate management?
Correct answer: B. TRAVERSE (Lincoff, NEJM 2023) identified a 50% relative excess of new atrial fibrillation in the testosterone arm vs placebo. New AF in a TRT recipient should trigger a pause and cardiology review. NICE NG196 governs AF management — assess CHA₂DS₂-VASc for stroke risk, decide on rate vs rhythm control, anticoagulate per the score. Reassess the TRT decision after the rhythm question is resolved — if symptomatic benefit is large, AF was incidental, and stroke prophylaxis is robust, TRT may continue with shared decision-making. Continuing TRT without AF management (A, D) ignores the trial signal. Permanent stop (C) is not always required. Switching preparation (E) does not change the testosterone exposure.
SBA 9 · GSM in a breast-cancer survivor · severe symptoms unresponsive to moisturisers
A 60-year-old woman, 3 years post-completion of treatment for ER-positive early breast cancer (no current adjuvant therapy beyond aromatase inhibitor completed 6 months ago), presents with severe vaginal dryness, dyspareunia, recurrent UTIs (3 in last 12 months), and avoidance of intimacy. She has tried Replens and Hyalofemme moisturisers consistently for 6 months with limited improvement. What is the most appropriate next step, per NICE NG215 / BMS 2024?
Correct answer: D. NICE NG215 and BMS 2024 endorse low-dose vaginal oestrogen for genitourinary syndrome of menopause in breast-cancer survivors after MDT / oncology agreement and adequate counselling. Systemic absorption is minimal at standard doses (Vagifem 10 microgram = 0.01 mg per insertion). Continuing moisturisers alone (A) ignores escalating symptoms. Systemic HRT (B) is generally avoided post-ER+ breast cancer. Fezolinetant (C) treats vasomotor symptoms, not GSM. Vaginal laser (E) is used in some specialist services but is second-line and should not pre-empt the standard low-dose vaginal oestrogen pathway.
SBA 10 · Perimenopausal contraception · 49-year-old on progestogen-only pill with VMS
A 49-year-old woman has been on the progestogen-only pill (desogestrel 75 microgram) for contraception for 4 years. Periods have stopped completely for 8 months. She now has severe vasomotor symptoms and would like HRT. BMI 24, BP 118/74, no migraine, no VTE history, no breast cancer history. What is the most appropriate management?
Correct answer: E. Desogestrel POP at 75 microgram does not provide reliable endometrial protection equivalent to HRT progestogen dosing; the FSRH and BMS 2024 advise that women using POP who add systemic oestrogen for HRT need additional endometrial protection — either a 52 mg LNG-IUS (which provides both contraception and HRT progestogen) or a separate HRT-dose progestogen alongside continuing POP. Adding oestrogen alone to POP (B) leaves inadequate endometrial protection. Stopping POP (A) loses contraception — at 49, contraception is required until age 55 or 12 months amenorrhoea (over 50) / 24 months (under 50, NICE NG23 + FSRH). COC (C) is generally not preferred at age 49 + when HRT is needed — transition to HRT instead. Tibolone (D) requires 12 months of natural amenorrhoea — uncertain in this patient on POP.
Self-marking. Ten items at AKT to CAS challenge level. Distribution of correct answers across the option letters is balanced. Eight or above = strong CAS-level competence on this body of material; 6–7 = solid AKT level; ≤ 5 = revisit the corresponding section before progressing. The full Menopause & Andropause CAS — a standalone FHEQ Level 7 award of 20 UK credits / 10 ECTS — is assessed by a confidence-calibrated applied-knowledge paper, a workplace capstone and a short defended presentation.
Now test yourself — and earn your CPD certificate
Answer the items, mark your work, add a reflection, and download a personalised CPD certificate.
Personalise your CPD certificate
Enter the name you would like to appear on your certificate. Stored locally in your browser only.
Four-quadrant blueprint
Clinical Dx ≥ 45 without FSH · POI workup · BSSM 2022 testosterone threshold · STRAW+10 · andropause + new AF on TRAVERSE backdrop.
Transdermal vs oral · LNG-IUS for HRT · migraine with aura · timing hypothesis · breast-cancer risk quantification.
BMS-RCOG 2024 pathway · low-risk early bleeding · risk-factor escalation · fezolinetant TA1143 · GSM in breast-cancer survivor · complex bleeding with major risk factor.
Secondary hypogonadism + fertility · perimenopausal contraception + HRT · TRT monitoring · testosterone for women HSDD · pre-conception in T2DM-CKD.
How it works. Select your answer for each item. Selection is recorded but not marked. When all twenty are answered, click Mark my answers. The results panel reveals the correct answer for each item plus a 60–120-word rationale focused on why the correct answer is correct, with one hyperlinked guideline reference per item. The certificate at the foot auto-populates with your name, date, score, quadrant breakdown, and personal reflection.
Q1 · Clinical diagnosis without FSH Diagnosis
A 47-year-old woman has 8 months of hot flashes, night sweats, sleep disturbance and irregular periods (last 6 weeks ago). BMI 27. No medications. Per NICE NG23 (2024 update), what is the most appropriate next step?
Q2 · POI workup Diagnosis
A 34-year-old woman with 5 months of secondary amenorrhoea, vasomotor symptoms and dyspareunia. Two FSH 4 weeks apart: 36 and 41 IU/L. AMH undetectable. Pregnancy test negative. Per ESHRE 2024 / Davis Lancet 2024, the next set of investigations before HRT initiation includes:
Q3 · BSSM 2022 testosterone threshold Diagnosis
A 58-year-old man with 18 months of low libido, ED, low mood. Two morning samples: total T 7.4 and 7.8 nmol/L; LH 6 and 7 IU/L (normal); FSH 5; PSA 1.2; Hb 148, Hct 0.42. BMI 28. Family complete. What is the most appropriate management?
Q4 · STRAW+10 staging Diagnosis
A 49-year-old woman has cycles of 21–55 days length variation over the last 12 months and a 75-day amenorrhoea interval. Vasomotor symptoms started 6 months ago. What is her STRAW+10 stage?
Q5 · ★ Professor-level Andropause + new-onset AF on TRAVERSE backdrop Diagnosis
A 64-year-old man started transdermal testosterone gel 8 months ago for confirmed testosterone deficiency — symptoms improved. He attends with new-onset palpitations and intermittent fluttering for 3 weeks. ECG confirms atrial fibrillation, rate 86. eGFR 72. He has hypertension (BP 138/84) and previous TIA on aspirin. What is the most appropriate management?
Q6 · HRT regimen for BMI 33 postmenopausal woman HRT regimens
A 50-year-old woman, BMI 33, has moderate-severe vasomotor symptoms. Last menstrual period 13 months ago. BP 130/80. No personal or family VTE or breast-cancer history. What is the most appropriate first-line HRT regimen?
Q7 · Mirena LNG-IUS for HRT HRT regimens
A 51-year-old woman has the Mirena 52 mg LNG-IUS in situ for 4 years for heavy menstrual bleeding. She now requests HRT for severe vasomotor symptoms. BMI 24. Which approach is most appropriate?
Q8 · Migraine with aura + perimenopause HRT regimens
A 49-year-old woman with 30-year history of migraine with aura has disabling night sweats, 2-hourly nocturnal awakenings and low mood for 9 months. Last period 4 months ago. BMI 27. BP 124/78. No VTE or breast-cancer history. Per BMS 2022, what is the most appropriate first-line HRT regimen?
Q9 · Timing hypothesis HRT regimens
A 53-year-old woman, 8 months post-menopause, asks about HRT for moderate vasomotor symptoms plus “is HRT good for my heart?”. No CVD; no breast-cancer history. What is the most accurate counselling per the timing hypothesis?
Q10 · ★ Professor-level Quantified breast cancer risk counselling HRT regimens
A 51-year-old woman wishes to start combined continuous HRT for vasomotor symptoms. BMI 26, no family history of premenopausal breast cancer, alcohol 6 units/week. She asks “how much extra breast cancer risk?” Per the NICE NG23 / BMS 2024 decision aid for women starting combined continuous HRT under age 55 for < 5 years, the most accurate quantitative counselling is:
Q11 · BMS-RCOG 2024 pathway — low-risk early bleeding Bleeding & non-hormonal
A 56-year-old woman attends with 3 weeks of light vaginal spotting. Started continuous combined HRT (transdermal oestradiol 50 mcg patch + micronised progesterone 100 mg daily) 5 months ago for vasomotor symptoms. BMI 28. No personal or family endometrial / breast / colorectal cancer. No diabetes / PCOS. Cervical screen up to date. Examination unremarkable. Per the BMS-RCOG 2024 pathway, what is the most appropriate next step?
Q12 · BMS-RCOG 2024 pathway — risk-factor escalation Bleeding & non-hormonal
A 62-year-old woman has 7 days of moderate vaginal bleeding. Started continuous combined HRT 14 months ago. BMI 31. No diabetes / PCOS. No family endometrial or colorectal cancer. Per BMS-RCOG 2024 pathway, what is the next step?
Q13 · Fezolinetant in breast-cancer survivor Bleeding & non-hormonal
A 54-year-old woman on tamoxifen for ER-positive breast cancer has 16 hot flashes/day, 4 nocturnal episodes, sleep collapse, PHQ-9 12. Oncologist has confirmed in writing that systemic HRT is not appropriate. BMI 25, ALT 22, eGFR 80. Per NICE TA1143, the most appropriate first-line non-hormonal pharmacological option is:
Q14 · GSM in breast-cancer survivor Bleeding & non-hormonal
A 60-year-old woman, 3 years post-completion of treatment for ER-positive early breast cancer (aromatase inhibitor completed 6 months ago), has severe vaginal dryness, dyspareunia, and recurrent UTIs. Tried Replens / Hyalofemme moisturisers consistently for 6 months, limited improvement. Per NICE NG215 / BMS 2024, the next step is:
Q15 · ★ Professor-level Complex bleeding with major risk factor Bleeding & non-hormonal
A 59-year-old woman attends with 5 weeks of progressively heavier vaginal bleeding (now requiring pad day/night). On transdermal oestradiol 75 mcg patch for 7 years + LNG-IUS in situ throughout (last replaced 7 years ago). BMI 42. T2DM 8 years on metformin and dapagliflozin. Cervical screen up to date. No Lynch / Cowden but father had colorectal cancer aged 71. Hb 102 g/L (down from 132). Examination unremarkable. Per BMS-RCOG 2024 pathway, the appropriate triage and pathway is:
Q16 · Secondary hypogonadism + fertility preservation Andropause & special pops
A 32-year-old man has 18 months of low libido, fatigue, ED. He is trying to conceive (2 years, no pregnancy). BMI 24. Two morning samples: total testosterone 6.8 and 7.1; LH 2.4 and 2.6 (low); FSH 3.0 (low); prolactin normal. Pituitary MRI normal. Semen analysis: low-normal motility and count. What is the most appropriate management?
Q17 · Perimenopausal contraception + HRT Andropause & special pops
A 49-year-old woman on desogestrel POP for 4 years; periods stopped 8 months ago. Now severe vasomotor symptoms, requesting HRT. BMI 24. No VTE / breast-cancer / migraine history. What is the appropriate management?
Q18 · TRT monitoring — erythrocytosis threshold Andropause & special pops
A 62-year-old man on transdermal testosterone gel for 6 months for confirmed testosterone deficiency. Symptoms improved. Bloods: total testosterone 19 nmol/L, Hb 175 g/L, Hct 0.55, PSA 1.4 (baseline 1.1). What is the appropriate action?
Q19 · Testosterone for women — HSDD Andropause & special pops
A 52-year-old postmenopausal woman on transdermal oestradiol + micronised progesterone for 9 months. Vasomotor symptoms resolved. Persistent low desire and reduced sexual responsiveness despite stable relationship. Total testosterone 0.4 nmol/L (low for female reference). Per BMS 2022, the most appropriate next step is:
Q20 · ★ Professor-level Pre-conception planning in T2DM-CKD Andropause & special pops
A 38-year-old NHS administrator with 6-year T2DM (HbA1c 71) on metformin, dapagliflozin, semaglutide, gliclazide, ramipril, indapamide, atorvastatin, ezetimibe, with eGFR 38 (down from 52), UACR 78, K⁺ 4.9, BMI 32, BP 138/86. Laser-treated proliferative retinopathy 2 y ago. Hopes to conceive within 12 months. Which combination of medication changes is required pre-conception?
Personal reflection — for your CPD portfolio
Two to four sentences are sufficient. Saved locally; auto-inserts onto the printable certificate below. Leave blank to use the supplied fallback wording.
MD Acumen School of Postgraduate Medicine
This certifies that
Your name will appear here
has completed the
Menopause & Andropause Synoptic Self-Assessment — 20 single-best-answer items at CAS tier
Authored by Prof Rajesh Varma · MD Acumen Ltd · mdacumen.com
Curriculum-aligned with NICE NG23 (2024 update); BMS 2024; BMS-RCOG-BSGE-BGCS-FSRH-GIRFT-RCGP 2024 unscheduled bleeding pathway; NICE TA1143; NICE NG215; BSSM 2022 testosterone guideline; ISSAM 2024; TRAVERSE 2023.
Continue your CPD journey
Key sources & further reading
All clinical content drawn from independent peer-reviewed and recognised guideline-issuing bodies. Where multiple licensed agents within a class are discussed, they are presented even-handedly per their NICE technology appraisals.
Expanded source list
Manley K, Hillard T, Clark J et al. Management of unscheduled bleeding on HRT: a joint guideline. Post Reproductive Health 2024. · NICE NG23 (2024 update). Menopause: identification and management. · NICE TA1143 (2024). Fezolinetant for moderate-severe vasomotor symptoms. · NICE NG215. Menopause: management of menopausal symptoms in patients with a history of, or at high risk of, breast cancer. · Hackett G et al. The British Society for Sexual Medicine guidelines on male adult testosterone deficiency. World J Mens Health 2022. · Lincoff AM, Bhasin S, Flevaris P et al. Cardiovascular safety of testosterone-replacement therapy (TRAVERSE). N Engl J Med 2023;389:107–117. · Davis SR, Pinkerton J, Santoro N, Simoncini T. Premature ovarian insufficiency: a Lancet Commission. Lancet 2024. · Panay N et al. IMS 2025 recommendations on women's midlife health and menopause. Climacteric 2025. · Lumsden M-A et al. ESE 2025 Clinical Practice Guideline on menopause and the perimenopause. Eur J Endocrinol 2025. · Lederman S et al. Fezolinetant for moderate-severe VMS (SKYLIGHT 1). Lancet 2023. · Johnson KA et al. SKYLIGHT 2. JCEM 2023. · Neal-Perry G et al. SKYLIGHT 4 long-term safety. Menopause 2024. · Schaudig K et al. Fezolinetant in women unsuitable for HRT (DAYLIGHT). BMJ 2024;387:e079525. · Pinkerton JV et al. Elinzanetant phase 3 (OASIS). JAMA 2024. · Ravindran N, Varma R. Cardiometabolic changes at menopause — time for precision menopause treatment. InnovAiT 2026. · Cho L et al. Rethinking menopausal hormone therapy: for whom, what, when, and how long. JACC 2023. · Mukherjee S et al. Update on menopause hormone therapy. Clin Endocrinol 2025. · Hickey M et al. Empowerment in menopause care. Lancet 2024. · NICE NG12. Suspected cancer: recognition and referral. · BMS Tools for Clinicians: HRT guide November 2022 / February 2026 update.
Ready for the full award?
This micro-course is Step 1. Step up to the NVU-awarded Menopause & Andropause CAS.
Micro Learning · The CAS · The CAS explained · Legal & Regulatory · enquiry@mdacumen.com